KLONOPIN RAPIDLY DISINTEGRATING
Clinical safety rating: caution
Comprehensive clinical and safety monograph for KLONOPIN RAPIDLY DISINTEGRATING (KLONOPIN RAPIDLY DISINTEGRATING).
Benzodiazepine; enhances GABA-A receptor activity by increasing the frequency of chloride channel opening, leading to neuronal hyperpolarization and inhibition.
| Metabolism | Primarily hepatic via CYP3A4-mediated reduction and glucuronidation; minor pathways include N-acetylation and oxidation. |
| Excretion | Renal (60-80% as metabolites, mainly glucuronide conjugates; <2% as unchanged drug). Biliary/fecal excretion accounts for ~10-20%. |
| Half-life | Terminal half-life 30-40 hours (range 19-60 h) in adults; accumulation occurs with repeated dosing, steady-state reached in 5-7 days. |
| Protein binding | 85-90% bound to albumin. |
| Volume of Distribution | 1.8-3.0 L/kg (extensive distribution into tissues; high lipid solubility). |
| Bioavailability | Oral (rapidly disintegrating tablet): ~90% (rapid and complete absorption, not affected by food; equivalent to conventional oral tablets). |
| Onset of Action | Oral (rapidly disintegrating tablet): 20-60 minutes for anxiolytic effect; 30-60 minutes for anticonvulsant effect (peak plasma concentration at 1-2 hours). |
| Duration of Action | Anxiolytic: 6-12 hours; anticonvulsant: 12-24 hours (due to long half-life, once or twice daily dosing provides sustained effect; tolerance may develop with chronic use). |
| Molecular Weight | 315.72 |
0.5 mg to 2 mg orally twice daily for anxiety; 0.5 mg to 1 mg orally three times daily for panic disorder. Maximum dose: 4 mg/day for panic disorder.
| Dosage form | TABLET, ORALLY DISINTEGRATING |
| Renal impairment | Clcr 10-50 mL/min: reduce to 75% of normal dose; Clcr <10 mL/min: reduce to 50% of normal dose. |
| Liver impairment | Child-Pugh Class A: no adjustment; Child-Pugh Class B or C: reduce dose by 50% and titrate cautiously. |
| Pediatric use | For seizure disorders (age <10 years or <30 kg): 0.01-0.03 mg/kg/day divided three times daily, titrate to 0.1-0.2 mg/kg/day. Not established for anxiety disorders. |
| Geriatric use | Initiate at 0.25 mg twice daily, titrate slowly to avoid oversedation, confusion, and fall risk. Maximum dose often limited to 2 mg/day. |
| 1st trimester | Avoid unless benefit outweighs risk; associated with congenital malformations (e.g., oral clefts) when used in first trimester. |
| 2nd trimester | Use only if clearly needed; risk of fetal benzodiazepine exposure may affect neurodevelopment. |
| 3rd trimester | Avoid; risk of neonatal withdrawal syndrome, hypotonia, respiratory depression, and floppy infant syndrome. |
Clinical note
Comprehensive clinical and safety monograph for KLONOPIN RAPIDLY DISINTEGRATING (KLONOPIN RAPIDLY DISINTEGRATING).
| Placental transfer | Complete transfer across placenta; serum levels in fetus approximate maternal levels. |
| Breastfeeding | Excreted into breast milk; may cause sedation, poor feeding, or weight loss in infant. Monitor infant for drowsiness and adequate weight gain. Use lowest effective dose for shortest duration. |
■ FDA Black Box Warning
Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for patients for whom alternative treatment options are inadequate.
| Serious Effects |
Hypersensitivity to clonazepam or any benzodiazepineSevere hepatic impairmentNarrow-angle glaucomaConcurrent use with opioids (except in supervised settings)Known severe respiratory insufficiency
| Precautions | Risk of dependence and withdrawal symptoms; tolerance may develop; concomitant use with CNS depressants; risk of respiratory depression; caution in hepatic impairment; may cause anterograde amnesia; not recommended in severe hepatic impairment; avoid abrupt discontinuation; may impair driving and other activities. |
| Food/Dietary | No significant food interactions. Grapefruit juice may theoretically increase clonazepam levels due to CYP3A4 inhibition, though risk is low; consider avoiding large quantities to be prudent. High-fat meals may slightly delay absorption but do not affect overall exposure. |
Loading safety data…
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | Pregnancy Category D. First trimester: Increased risk of congenital malformations, particularly cleft lip/palate, cardiac defects, and neural tube defects. Late third trimester: Risk of neonatal withdrawal syndrome (irritability, tremors, hypertonia) and floppy infant syndrome (hypotonia, lethargy, poor feeding). |
| Fetal Monitoring | Maternal: Monitor for CNS depression, respiratory depression, and cognitive impairment. Fetal: Ultrasound for fetal growth and anatomy. Neonatal: Observe for signs of withdrawal (irritability, hypertonia, tremors) and floppy infant syndrome (hypotonia, lethargy) for at least 48 hours after delivery. |
| Fertility Effects | Clonazepam may disrupt menstrual cycle and ovulation, potentially reducing fertility. Long-term use associated with sexual dysfunction (decreased libido, erectile dysfunction) in both sexes. However, effects are reversible upon discontinuation. |
| Clinical Pearls | Orally disintegrating tablet (ODT) formulation allows administration without water, useful for patients with swallowing difficulties or when water access is limited. Ensure dry hands when handling to prevent premature dissolution. Onset of action is similar to conventional tablets (30-60 min). Bioavailability is approximately 90% with no significant food effect. Avoid use in patients with severe hepatic impairment (Child-Pugh C). Withdrawal seizures may occur upon abrupt discontinuation; taper gradually. Caution with concomitant CNS depressants due to additive sedation. |
| Patient Advice | Remove the tablet from the blister pack with dry hands just before taking it. · Place the tablet on your tongue; it will dissolve rapidly without water. · Do not crush, chew, or swallow the tablet whole. · Wait until the tablet has dissolved completely before swallowing. · Avoid drinking or eating immediately after taking, as this may wash away the medication. · Do not stop taking this medication suddenly without consulting your doctor, as withdrawal seizures may occur. · This medication may cause drowsiness, dizziness, or impaired coordination; avoid driving or operating machinery until you know how it affects you. · Avoid alcohol while taking this medication, as it increases sedation and risk of side effects. · Inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding. · Store at room temperature away from moisture and heat. Keep the tablets in the original blister pack until use. |